Therma Bright (TSXV: THRM; OTCQB: TBRIF), has announced the addition of Douglas S. Sommerville to its advisory board.
In a statement, Rob Fia, CEO of Therma Bright, said, “Doug is highly respected across North America and internationally, with established relationships within the medical retail space, hospital management, medical practitioner networks, and key industry leaders and associations. His deep expertise in the pharmaceutical and medical device sectors will be invaluable to our business development efforts with Venowave and Digital Cough Analyzer, as well as our investment partners at Inretio, InStatin, and InVixa.”
Previously, Mr. Sommerville served as the head of country for Teva Canada Limited, where he oversaw the Canadian operations of Teva’s generic drug business, the pharmaceutical firm’s third-largest global subsidiary, with sales exceeding $1.3 billion. Prior to this role, he was the Global Vice President of Infusion Systems at Baxter Healthcare International. Furthermore, Mr. Summerville served as chairman of the Canadian Generic Pharmaceutical Association until his retirement from Teva in 2018.
